# aMoon Fund

> aMoon Fund is a VC fund in Ra'anana backing Health Care and Biotechnology. See 79 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Ra'anana, Israel
- Total investments: 79
- Last investment: Jun 2026
- Lead investor: 49%
- Last fund: Jul 2022
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/amoon-fund/
- X (Twitter): https://twitter.com/amoonfund?lang=en
- Website: https://amoon.fund/

aMoon Fund is a VC fund in Ra'anana focused on Health Care and Biotechnology. aMoon is a leading healthtech & life sciences venture fund founded by Marius Nacht and Dr. Yair Schindel. Their team is passionate about building successful businesses and helping biopharma, digital health and medical technology companies realize their potential. They partner with management teams who use technology and cutting-edge science toaccelerate cures for the world’s most life-threatening conditions and those providing solutions for global healthcare’s biggest cost drivers.

## Contacts

5 contacts available for aMoon Fund. Shizune tracks 9 team members at aMoon Fund. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/amoon?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $5.7M–$82M |
| Series B | $22M–$93M |
| Series C | $30M–$82M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 34 | 43% |
| Biotechnology | 28 | 35% |
| Medical | 22 | 28% |
| Life Science | 9 | 11% |
| Medical Device | 9 | 11% |

40 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 17 | 22% |
| Series A | 15 | 19% |
| Series C | 11 | 14% |
| Funding Round | 6 | 8% |
| Venture - Series Unknown | 6 | 8% |

12 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 30 | 38% |
| Israel | 17 | 22% |
| France | 1 | 1% |
| Switzerland | 1 | 1% |
| United Kingdom | 1 | 1% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Moshe Mor | General Partner | 14 | https://shizune.co/investors/profile/moshe-mor |
| Gur Roshwalb | Managing Director | 4 | https://shizune.co/investors/profile/gur-roshwalb |
| Itay Bengad | Executive in Residence | 0 | https://shizune.co/investors/profile/itay-bengad-endovitech |
| Marius Nacht | Founder & Anchor Investor | 34 | https://shizune.co/investors/profile/marius-nacht |
| Michal Goren Miller | Chief Legal Counsel & Chief Compliance Officer | 0 | https://shizune.co/investors/profile/michal-goren-miller |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Connie Health | Connie Health empowers older Americans to make confident, worry-free healthcare decisions. | $40M | Series B | Jun 18, 2026 |  |
| Lin Health | Online integrative pain management. | $11M | Series A | Dec 08, 2025 |  |
| Adcytherix | Adcytherix is a biopharmaceutical firm that specializes in the development of new antibody drug conjugates (ADC) to treat diseases with a high unmet need, including cancer. | $122.8M | Series A | Oct 16, 2025 |  |
| KAHR medical | KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders. | $22M | Series B | Oct 15, 2025 |  |
| Iantrek | Iantrek develops technology for minimally invasive microinvasive glaucoma surgery. It was founded in 2019 and is based in White Plains, New York. | $42M | Series C | Aug 20, 2025 |  |
| Iantrek | Iantrek develops technology for minimally invasive microinvasive glaucoma surgery. It was founded in 2019 and is based in White Plains, New York. | $42M | Series C | Aug 20, 2025 |  |
| Positive Development | Positive Development is improving lives by helping develop the skills to connect with one’s self, family, and community. The company also provides mental and physical health services to children with developmental challenges and their families. They focus on the relationships between parents, caregivers, therapists, and children. Their researchvalidated model is grounded in a deep understanding of the natural and joyful ways that children acquire and strengthen social-emotional skills. Positive Development was founded in 2019 and is based in Washington, DC, USA. | $51.5M | Series C | Aug 05, 2025 |  |
| Magentiq Eye Ltd | Magentiq Eye Ltd. was established in 2014 with the aim to harness the most cutting edge computer vision and deep learning techniques to aid doctors in endoscopic procedures. Doctors today spend hours during Endoscopic Procedures looking at the LCD screens in order to explore, examine and treat various conditions. At Magentiq Eye we put the growingpower of Deep Learning, Image and Video Processing to the help of doctors, so they can be more accurate and effective- ultimately saving millions of lives and billions of dollars. Our first product is APDS: Automatic Polyp Detection System, developed to be used in online and offline colonoscopies. Our APDS (Automatic Polyp Detection System) can point out the suspicious locations of polyps in the videos, increasing the attentiveness of doctors during procedures, thus helping them to reduce their polyp miss-rates. Given the large population that annually undergoes colonoscopy, even a modest decrease in polyp miss-rate can save a lot of lives! The APDS- RT runs on the video feed from the endoscopic camera used by the physician in real time during the endoscopic procedure (currently only on Colonoscopy Procedure). The APDS-OFL is a software that runs in off-line mode on pre-Recorded Colonoscopy Videos. It is estimated that 40 million colonoscopy procedures are performed every year (almost 40% in the US alone). The ability of colonoscopy procedures to decrease the number of colon cancer cases has been proven without a doubt and their number expected to grow. However, researches have shown that there is about 25% of misses (undetected polyps) in those procedures, misses which can, unfortunately, cause interval cancer. Within this context The APDS can be sold as an add-on to the colonoscopy system or as a service (license per exam), paid by the clinic or hospital. Once the APDS system would be formally proven, during the next year, to improve polyp detection rate, it could be sold either jointly with the endoscopic equipment providers or it can be integrated in the colonoscopy devices. |  | Series A | Jul 30, 2025 |  |
| Character Biosciences | Biopharmaceutical research and development company that's an affiliate of Clover Health | $93M | Series B | Mar 25, 2025 |  |
| Character Biosciences | Biopharmaceutical research and development company that's an affiliate of Clover Health | $93M | Series B | Mar 25, 2025 |  |

10 of 79 investments shown.

## Co-investors
- [Lightspeed Venture Partners](https://shizune.co/investors/profile/lightspeed-venture-partners) — VC Fund, 12 deals together
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund, 7 deals together
- [Catalio Capital Management](https://shizune.co/investors/profile/catalio-capital-management) — VC Fund, 7 deals together
- [Peregrine Ventures](https://shizune.co/investors/profile/peregrine-ventures) — VC Fund, 7 deals together
- [Fidelity](https://shizune.co/investors/profile/fidelity-investments) — VC Fund, 5 deals together
- [Invus](https://shizune.co/investors/profile/invus) — VC Fund, 5 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [F6 Ventures](https://shizune.co/investors/profile/flat6labs) — VC Fund
- [Oqal](https://shizune.co/investors/profile/oqal) — VC Fund
- [Alesta Yatırım](https://shizune.co/investors/profile/alesta-girisim) — VC Fund

## Featured in investor lists
- [Health Care Investors in Middle East](https://shizune.co/investors/health-care-investors-middle-east)
- [Health Care VC Funds in Middle East](https://shizune.co/investors/health-care-vc-funds-middle-east)
- [Health Care VC Funds in Israel](https://shizune.co/investors/health-care-vc-funds-israel)
- [Biotechnology Investors in Middle East](https://shizune.co/investors/biotechnology-investors-middle-east)
- [Biotechnology VC Funds in Middle East](https://shizune.co/investors/biotechnology-vc-funds-middle-east)
- [Biotech Investors in Middle East](https://shizune.co/investors/biotech-investors-middle-east)

## FAQ

### What does aMoon Fund invest in?

aMoon Fund invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series A stage. Most of the 79 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is aMoon Fund's check size?

aMoon Fund typically joins rounds of $5.7M–$82M at Series A, $22M–$93M at Series B and $30M–$82M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds aMoon Fund participates in.

### How do I contact aMoon Fund?

Public channels for aMoon Fund include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at aMoon Fund?

The team at aMoon Fund includes Moshe Mor (General Partner), Gur Roshwalb (Managing Director) and Itay Bengad (Executive in Residence), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co